Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmedetomidine + bupivacaine + fentanyl
- Development stage
- Phase 4
- Lead developer
- King Abdulaziz Medical City
- Modality
- Small Molecules
- Administration
- Intrathecal, Intravenous
01
Overview
This drug entry refers to a combination regimen consisting of the alpha-2 adrenergic agonist dexmedetomidine, the local anesthetic bupivacaine, and the opioid analgesic fentanyl. This specific combination is being evaluated in a Phase 4 clinical trial sponsored by King Abdulaziz Medical City to determine the effects of dexmedetomidine as an adjuvant to spinal anesthesia in patients undergoing orthopedic surgery. The study compares two interventional protocols: one where dexmedetomidine is administered intrathecally alongside bupivacaine and fentanyl, and another where it is administered intravenously following a spinal block of bupivacaine and fentanyl. The primary goal is to assess the prolongation of spinal anesthesia and the time of motor block regression.
- Brand names
- DemexaBucaineMartindale pharma Fentanyl
02
Targets
ADRA2A (α2A)MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on dexmedetomidine + bupivacaine + fentanyl.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmedetomidine + bupivacaine + fentanyl.